产前脑桥ID1信号通路在弥漫性中线胶质瘤中的治疗靶向研究
该研究探讨弥漫性中线胶质瘤(DMG)中ID1蛋白在H3K27M突变和脑桥位置下的表达上调及其治疗靶向性。通过全外显子、RNA和ChIP测序及细胞迁移侵袭实验,发现遗传学和药理学(大麻二酚,CBD)抑制ID1可减少肿瘤细胞侵袭/迁移和肿瘤生长,患者报告的CBD数据提示标准化给药的临床试验可能有益。
要点
- 人DMG和宫内电穿孔小鼠肿瘤中ID1表达增高与H3K27M突变及脑桥位置相关。
- 遗传学和药理学(CBD)抑制ID1可降低H3.3/H3.1K27M PPK-IUE和人DIPGXIIIP*体内模型中的肿瘤细胞侵袭/迁移和肿瘤生长。
- CBD对细胞增殖的影响似乎非ID1介导;患者报告的CBD数据提示标准化给药的临床试验可能有益。
核心结论
- H3K27M介导的ID1在DMG中的再激活导致SPARCL1+迁移转录程序,该程序可被CBD治疗靶向。
研究设计与样本
- 对DMG组织中ID1基因座进行全外显子、RNA和ChIP测序。
- 对培养细胞进行shRNA介导的ID1敲低后的划痕迁移和Transwell侵袭实验。
- 在体外和体内评估ID1对DMG肿瘤生长的遗传学和药理学(大麻二酚,CBD)抑制。
- 收集患者报告的CBD给药信息。
主要发现
- 人DMG和宫内电穿孔小鼠肿瘤中ID1表达增高与H3K27M突变和脑桥位置相关。
- ChIP测序显示ID1调控区域在人H3K27M-DMG肿瘤和产前脑桥细胞中表观遗传活跃。
- 高表达ID1的星形胶质细胞样DMG细胞与发育中人脑的少突/星形前体细胞(OAPCs)共享转录程序,并显示迁移调控蛋白SPARCL1上调。
- 遗传学和药理学(CBD)抑制ID1可降低H3.3/H3.1K27M PPK-IUE和人DIPGXIIIP* pHGG体内模型中的肿瘤细胞侵袭/迁移和肿瘤生长。
- CBD对细胞增殖的影响似乎非ID1介导。
临床怎么用
- 患者报告的CBD治疗数据提示,标准化给药的临床试验可能有益(作者认为)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis and limited understanding of the mechanism behind tumor invasion. Previous reports demonstrate upregulation of the protein ID1 with H3K27M and ACVR1 mutations in DMG, but this has not been confirmed in human tumors or therapeutically targeted. METHODS: Whole exome, RNA, and ChIP-sequencing was performed on the ID1 locus in DMG tissue. Scratch-assay migration and transwell invasion assays of cultured cells were performed following shRNA-mediated ID1-knockdown. In vitro and in vivo genetic and pharmacologic [cannabidiol (CBD)] inhibition of ID1 on DMG tumor growth was assessed. Patient-reported CBD dosing information was collected. RESULTS: Increased ID1 expression in human DMG and in utero electroporation (IUE) murine tumors is associated with H3K27M mutation and brainstem location. ChIP-sequencing indicates ID1 regulatory regions are epigenetically active in human H3K27M-DMG tumors and prenatal pontine cells. Higher ID1-expressing astrocyte-like DMG cells share a transcriptional program with oligo/astrocyte-precursor cells (OAPCs) from the developing human brain and demonstrate upregulation of the migration regulatory protein SPARCL1. Genetic and pharmacologic (CBD) suppression of ID1 decreases tumor cell invasion/migration and tumor growth in H3.3/H3.1K27M PPK-IUE and human DIPGXIIIP* in vivo models of pHGG. The effect of CBD on cell proliferation appears to be non-ID1 mediated. Finally, we collected patient-reported CBD treatment data, finding that a clinical trial to standardize dosing may be beneficial. CONCLUSIONS: H3K27M-mediated re-activation of ID1 in DMG results in a SPARCL1+ migratory transcriptional program that is therapeutically targetable with CBD.
引用
- Messinger D, Harris MK, Cummings JR, et al. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro Oncol. 2023. PMID: 35605606. doi:10.1093/neuonc/noac141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。